Chemotherapy-induced cardiomyopathy

References

• Fuster V, Voute J. MDGs: chronic diseases are not on the agenda. Lancet366(9496), 1512–1514 (2005).
   PubMed Web of Science ®Google Scholar
• Armstrong GT, Liu Q, Yasui Y et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J. Clin. Oncol.27(14), 2328–2338 (2009).
   PubMed Web of Science ®Google Scholar
• Tukenova M, Guibout C, Oberlin O et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J. Clin. Oncol.28(8), 1308–1315 (2010).
   PubMed Web of Science ®Google Scholar
• van Dalen EC, van den Brug M, Caron HN, Kremer LC. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur. J. Cancer42(18), 3199–3205 (2006).
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Graham T, Hurwitz R et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children’s Cancer Study Group. Pediatrics89(5 Pt 1), 942–949 (1992).
   PubMed Web of Science ®Google Scholar
• Schwartz RG, McKenzie WB, Alexander J et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am. J. Med.82(6), 1109–1118 (1987).
   PubMed Web of Science ®Google Scholar
• Tjeerdsma G, Meinardi MT, van Der Graaf WT et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart81(4), 419–423 (1999).
   PubMed Web of Science ®Google Scholar
• Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J. Am. Coll. Cardiol.20(1), 62–69 (1992).
   PubMed Web of Science ®Google Scholar
• Ganz WI, Sridhar KS, Forness TJ. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate. Am. J. Clin. Oncol.16(2), 109–112 (1993).
   PubMed Web of Science ®Google Scholar
• Morandi P, Ruffini PA, Benvenuto GM, La Vecchia L, Mezzena G, Raimondi R. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m2) cyclophosphamide. Bone Marrow Transplant.28(3), 277–282 (2001).
   PubMed Web of Science ®Google Scholar
• Ewer MS, Ali MK, Mackay B et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J. Clin. Oncol.2(2), 112–117 (1984).
   PubMed Web of Science ®Google Scholar
• Jassal DS, Han SY, Hans C et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline-mediated cardiomyopathy. J. Am. Soc. Echocardiogr.22(4), 418–424 (2009).
   PubMed Web of Science ®Google Scholar
• Hoit BD. Detection of myocardial dysfunction during cancer chemotherapy with tissue Doppler imaging: a canary in the coal mine? J. Am. Soc. Echocardiogr.22(4), 425–426 (2009).
   PubMed Web of Science ®Google Scholar
• Urbanova D, Urban L, Carter A, Maasova D, Mladosievicova B. Cardiac troponins – biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma53(3), 183–190 (2006).
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation109(22), 2749–2754 (2004).
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol.36(2), 517–522 (2000).
   PubMed Web of Science ®Google Scholar
• Price JF, Thomas AK, Grenier M et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation114(10), 1063–1069 (2006).
   PubMed Web of Science ®Google Scholar
• Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J. Am. Coll. Cardiol.39(2), 202–209 (2002).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Hayashi D, Yamazaki T et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J.136(2), 362–363 (1998).
   PubMed Web of Science ®Google Scholar
• Okumura H, Iuchi K, Yoshida T et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol.104(4), 158–163 (2000).
   PubMed Web of Science ®Google Scholar
• Nousiainen T, Vanninen E, Jantunen E et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J. Intern. Med.251(3), 228–234 (2002).
   PubMed Web of Science ®Google Scholar
• Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J. Am. Coll. Cardiol.48(1), 1–11 (2006).
   PubMed Web of Science ®Google Scholar
• Tulevski, II, Wolde MT, van Veldhuisen DJ et al. Combined utility of brain natriuretic peptide and cardiac troponine T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. Int. J. Cardiol.116(2), 161–166 (2006).
   PubMed Web of Science ®Google Scholar
• Favory R, Neviere R. Bench-to-bedside review: significance and interpretation of elevated troponin in septic patients. Crit. Care10(4), 224 (2006).
   PubMed Web of Science ®Google Scholar
• Polena S, Shikara M, Naik S et al. Troponin I as a marker of doxorubicin induced cardiotoxicity. Proc. West Pharmacol. Soc.48, 142–144 (2005).
   PubMedGoogle Scholar
• Gaze DC, Collinson PO. Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection. Expert Opin. Drug Metab. Toxicol.1(4), 715–725 (2005).
   PubMedGoogle Scholar
• Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma. Eur. J. Haematol.62(2), 135–141 (1999).
   PubMed Web of Science ®Google Scholar
• van Royen N, Jaffe CC, Krumholz HM et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am. J. Cardiol.77(10), 843–850 (1996).
   PubMed Web of Science ®Google Scholar
• Ko SM, Kim YJ, Park JH, Choi NM. Assessment of left ventricular ejection fraction and regional wall motion with 64-slice multidetector CT: a comparison with two-dimensional transthoracic echocardiography. Br. J. Radiol.83(985), 28–34 (2010).
   PubMed Web of Science ®Google Scholar
• Gallagher MJ, Ross MA, Raff GL, Goldstein JA, O’Neill WW, O’Neil B. The diagnostic accuracy of 64-slice computed tomography coronary angiography compared with stress nuclear imaging in emergency department low-risk chest pain patients. Ann. Emerg. Med.49(2), 125–136 (2007).
   PubMed Web of Science ®Google Scholar
• Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol.23(31), 7820–7826 (2005).
   PubMed Web of Science ®Google Scholar
• Panjrath GS, Jain D. Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging. J. Nucl. Cardiol.13(3), 415–426 (2006).
   PubMed Web of Science ®Google Scholar
• Flotats A, Carrio I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur. J. Nucl. Med. Mol. Imaging30(4), 615–630 (2003).
   PubMed Web of Science ®Google Scholar
• Boogers MJ, Fukushima K, Bengel FM, Bax JJ. The role of nuclear imaging in the failing heart: myocardial blood flow, sympathetic innervation, and future applications. Heart Fail. Rev. DOI: 10.1007/s10741-010-9196-0 (2010) (Epub ahead of print).
   Google Scholar
• Carrio I, Estorch M, Berna L, Lopez-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J. Nucl. Med.36(11), 2044–2049 (1995).
   PubMed Web of Science ®Google Scholar
• Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu. Rev. Med.57, 485–498 (2006).
   PubMed Web of Science ®Google Scholar
• Ali MK, Ewer MS, Gibbs HR, Swafford J, Graff KL. Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer74(1), 182–188 (1994).
   PubMed Web of Science ®Google Scholar
• Banks J, Marmot M, Oldfield Z, Smith JP. Disease and disadvantage in the United States and in England. JAMA295(17), 2037–2045 (2006).
   PubMed Web of Science ®Google Scholar
• Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA291(20), 2441–2447 (2004).
   PubMed Web of Science ®Google Scholar
• Zambetti M, Moliterni A, Materazzo C et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J. Clin. Oncol.19(1), 37–43 (2001).
   PubMed Web of Science ®Google Scholar
• Yeh ET, Tong AT, Lenihan DJ et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation109(25), 3122–3131 (2004).
   PubMed Web of Science ®Google Scholar
• Mulrooney DA, Yeazel MW, Kawashima T et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ339, b4606 (2009).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med.91(5), 710–717 (1979).
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer97(11), 2869–2879 (2003).
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA266(12), 1672–1677 (1991).
   PubMed Web of Science ®Google Scholar
• Hequet O, Le QH, Moullet I et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J. Clin. Oncol.22(10), 1864–1871 (2004).
   PubMed Web of Science ®Google Scholar
• No authors listed. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet355(9217), 1757–1770 (2000).
   PubMed Web of Science ®Google Scholar
• Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog. Cardiovasc. Dis.53(2), 105–113 (2010).
   PubMed Web of Science ®Google Scholar
• Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann. Intern. Med.125(1), 47–58 (1996).
   PubMed Web of Science ®Google Scholar
• Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, Mercadier JJ. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. Faseb J.13(12), 1501–1510 (1999).
   PubMed Web of Science ®Google Scholar
• Falcone G, Filippelli W, Mazzarella B et al. Cardiotoxicity of doxorubicin: effects of 21-aminosteroids. Life Sci.63(17), 1525–1532 (1998).
   PubMed Web of Science ®Google Scholar
• Bordoni A, Biagi P, Hrelia S. The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes. Biochim. Biophys. Acta1440(1), 100–106 (1999).
   PubMed Web of Science ®Google Scholar
• Unverferth DV, Fertel RH, Talley RL, Magorien RD, Balcerzak SP. The effect of first-dose doxorubicin on the cyclic nucleotide levels of the human myocardium. Toxicol. Appl. Pharmacol.60(1), 151–154 (1981).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Sallan SE et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation96(8), 2641–2648 (1997).
   PubMed Web of Science ®Google Scholar
• Maeda A, Honda M, Kuramochi T, Takabatake T. Doxorubicin cardiotoxicity: diastolic cardiac myocyte dysfunction as a result of impaired calcium handling in isolated cardiac myocytes. Jpn Circ. J.62(7), 505–511 (1998).
   PubMedGoogle Scholar
• Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep.62(6), 865–872 (1978).
   PubMedGoogle Scholar
• Billingham M, Bristow MR. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat. Symp.3, 71–76 (1984).
   Google Scholar
• Gaudin PB, Hruban RH, Beschorner WE et al. Myocarditis associated with doxorubicin cardiotoxicity. Am. J. Clin. Pathol.100(2), 158–163 (1993).
   PubMed Web of Science ®Google Scholar
• Topalov V, Popovic K, Cikos J, Pejin D, Uzurov V. [Cardiotoxic aspects of daunorubicin used in the treatment of acute myeloblastic and lymphoblastic leukoses]. Med. Pregl.34(3–4), 119–122 (1981).
   PubMedGoogle Scholar
• Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol.131(5), 561–578 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin. Oncol.28(1 Suppl. 3), 13–19 (2001).
   PubMed Web of Science ®Google Scholar
• Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol.20(5), 1215–1221 (2002).
   PubMed Web of Science ®Google Scholar
• Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA240(15), 1603–1606 (1978).
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol.55(3), 213–220 (2010).
   PubMed Web of Science ®Google Scholar
• Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin. Drug Saf.5(6), 791–809 (2006).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med.351(2), 145–153 (2004).
   PubMed Web of Science ®Google Scholar
• Felker GM, Thompson RE, Hare JM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med.342(15), 1077–1084 (2000).
   PubMed Web of Science ®Google Scholar
• Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol.48(11), 2258–2262 (2006).
   PubMed Web of Science ®Google Scholar
• Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer104(11), 2492–2498 (2005).
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell103(2), 211–225 (2000).
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature344(6263), 251–253 (1990).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc.83(6), 679–686 (2008).
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med.12(8), 908–916 (2006).
   PubMed Web of Science ®Google Scholar
• Kerkela R, Woulfe KC, Durand JB et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci.2(1), 15–25 (2009).
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet370(9604), 2011–2019 (2007).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Autorino R, Bruni G et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann. Oncol.20(9), 1535–1542 (2009).
   PubMed Web of Science ®Google Scholar
• Machiels JP, Bletard N, Pirenne P, Jacquet L, Bonbled F, Duck L. Acute cardiac failure after sunitinib. Ann. Oncol.19(3), 597–599 (2008).
   PubMedGoogle Scholar
• Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood110(4), 1233–1237 (2007).
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med.12(8), 908–916 (2006).
   PubMed Web of Science ®Google Scholar
• Sprycel®. Prescribing information. Bristol-Myers Squibb Company, NJ, USA (2006).
   Google Scholar
• Champion JC. Cardiotoxicity of other chemotherapeutic agents. In: Cancer and the Heart. BC Decker Inc., ON, Canada, 115–128 (2006).
   Google Scholar
• Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant.12(2), 169–172 (1993).
   PubMed Web of Science ®Google Scholar
• Kupari M, Volin L, Suokas A, Timonen T, Hekali P, Ruutu T. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant.5(2), 91–98 (1990).
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Piccart MJ. The bigger the better? …or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann. Oncol.8(12), 1177–1182 (1997).
   PubMed Web of Science ®Google Scholar
• Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones RB. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol. Blood Marrow Transplant.6(2A), 198–203 (2000).
   PubMed Web of Science ®Google Scholar
• Quezado ZM, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann. Intern. Med.118(1), 31–36 (1993).
   PubMed Web of Science ®Google Scholar
• Klastersky J. Side effects of ifosfamide. Oncology65(Suppl. 2), 7–10 (2003).
   PubMed Web of Science ®Google Scholar
• Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother. Pharmacol.24(6), 395–396 (1989).
   PubMed Web of Science ®Google Scholar
• Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev.30(2), 181–191 (2004).
   PubMed Web of Science ®Google Scholar
• Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol.18(8), 1725–1732 (2000).
   PubMed Web of Science ®Google Scholar
• Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb. Res.99(5), 503–509 (2000).
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer112(9), 1949–1953 (2008).
   PubMed Web of Science ®Google Scholar
• Shao Y, Pardini L, Pardini RS. Enhancement of the antineoplastic effect of mitomycin C by dietary fat. Cancer Res.54(24), 6452–6457 (1994).
   PubMed Web of Science ®Google Scholar
• Verweij J, Funke-Kupper AJ, Teule GJ, Pinedo HM. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med. Oncol. Tumor Pharmacother.5(3), 159–163 (1988).
   PubMedGoogle Scholar
• Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann. Oncol.1(6), 409–414 (1990).
   PubMed Web of Science ®Google Scholar
• Kuropkat C, Griem K, Clark J, Rodriguez ER, Hutchinson J, Taylor SG 4th. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am. J. Clin. Oncol.22(5), 466–470 (1999).
   PubMed Web of Science ®Google Scholar
• Schober C, Papageorgiou E, Harstrick A et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer72(7), 2242–2247 (1993).
   PubMed Web of Science ®Google Scholar
• Bathina JD, Yusuf SW. 5-fluorouracil-induced coronary vasospasm. J. Cardiovasc. Med. (Hagerstown)11(4), 281–284 (2010).
   PubMed Web of Science ®Google Scholar
• Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol.13(1), 180–190 (1995).
   PubMed Web of Science ®Google Scholar
• Seidman AD, Reichman BS, Crown JP et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J. Clin. Oncol.13(5), 1152–1159 (1995).
   PubMed Web of Science ®Google Scholar
• Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin. Oncol.23(5 Suppl. 11), 23–27 (1996).
   PubMed Web of Science ®Google Scholar
• Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors. J. Clin. Oncol.16(11), 3483–3485 (1998).
   PubMed Web of Science ®Google Scholar
• Dillman RO. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest.19(8), 833–841 (2001).
   PubMed Web of Science ®Google Scholar
• Kilickap S, Yavuz B, Aksoy S et al. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin’s lymphoma. Med. Oncol.25(4), 437–442 (2008).
   PubMed Web of Science ®Google Scholar
• Oshima K, Sakata-Yanagimoto M, Asano-Mori Y et al. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplant.36(9), 821–824 (2005).
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood104(3), 655–658 (2004).
   PubMed Web of Science ®Google Scholar
• Basquiera AL, Berretta AR, Garcia JJ, Palazzo ED. Coronary ischemia related to alemtuzumab therapy. Ann. Oncol.15(3), 539–540 (2004).
   PubMed Web of Science ®Google Scholar
• Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther.28(11), 1779–1802 (2006).
   PubMed Web of Science ®Google Scholar
• D’Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol.23(28), 7135–7142 (2005).
   PubMed Web of Science ®Google Scholar
• Ewer MS, Perez EA, Baselga J et al. Cardiac Safety Guidelines for the adjuvant use of trastuzumab (Herceptin) in HER-2 positive breast cancer. Presented at: St.Gallen 10th International Conference on Primary Therapy of Early Breast Cancer. St Gallen, Switzlerland, 14–17 March 2007.
   Google Scholar
• Mackey JR, Clemons M, Cote MA et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr. Oncol.15(1), 24–35 (2008).
   PubMed Web of Science ®Google Scholar
• Procter M, Suter TM, de Azambuja E et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J. Clin. Oncol.28(21), 3422–3428 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen MC, Huberman MS, Nesto RW. Recombinant α2 interferon-related cardiomyopathy. Am. J. Med.85(4), 549–551 (1988).
   PubMed Web of Science ®Google Scholar
• Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by interferon. BMJ300(6733), 1174–1175 (1990).
   PubMedGoogle Scholar
• Deyton LR, Walker RE, Kovacs JA et al. Reversible cardiac dysfunction associated with interferon α therapy in AIDS patients with Kaposi’s sarcoma. N. Engl. J. Med.321(18), 1246–1249 (1989).
   PubMed Web of Science ®Google Scholar
• Zimmerman S, Adkins D, Graham M et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon α therapy. Cancer Biother.9(4), 291–299 (1994).
   PubMedGoogle Scholar
• Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation112(12), E154–E235 (2005).
   PubMed Web of Science ®Google Scholar
• Sarkiss MG, Yusuf SW, Warneke CL et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer109(3), 621–627 (2007).
   PubMed Web of Science ®Google Scholar
• Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann. Oncol.13(5), 699–709 (2002).
   PubMed Web of Science ®Google Scholar
• Cadeddu C, Piras A, Mantovani G et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am. Heart J.160(3), 487.e1–e7 (2010).
   PubMedGoogle Scholar
• Tallaj JA, Franco V, Rayburn BK et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J. Heart Lung Transplant.24(12), 2196–2201 (2005).
   PubMed Web of Science ®Google Scholar
• Iliescu C, Yusuf SW, Swafford J. Impact of angiotensin converting enzyme inhibitors and carvedilol on recovery of cardiac function in Imatinib (gleevac) associated cardiomyopathy. J. Cardiac Fail.11(Suppl.), 54 (2005).
   Google Scholar
• Shukla A, Yusuf SW, Daher I, Lenihan DJ, Durand JB. High mortality rates are associated with withdrawal of β blockers and ace-inhibitors in chemotherapy induced heart failure. Circulation118, S797 (2008).
   Google Scholar
• Shaik N, Yusuf SW, Swafford J et al. The role of valsartan and carvedilol in patients with chemotherapy associated cardiomyopathy who are intolerant to angiotensin converting enzyme inhibitors. J. Cardiac Fail. (Suppl. 11), 87 (2005).
   PubMed Web of Science ®Google Scholar
• Woods ML, Yusuf SW, Swafford J et al. Milrinone and carvedilol in medical management of chemotherapy induced acute decompensated class 1V heart failure. J. Cardiac Fail.8(Suppl.), 296 (2002).
   Google Scholar
• Rickard J, Kumbhani DJ, Baranowski B, Martin DO, Tang WH, Wilkoff BL. Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy. Am. J. Cardiol.105(4), 522–526 (2010).
   PubMed Web of Science ®Google Scholar
• Ganame J, Claus P, Eyskens B et al. Acute cardiac functional and morphological changes after anthracycline infusions in children. Am. J. Cardiol.99(7), 974–977 (2007).
   PubMed Web of Science ®Google Scholar
• Nexavar® package insert. Bayer Health Care Pharmaceuticals, CA, USA (2009).
   Google Scholar
• Khakoo AY, Kassiotis CM, Tannir N et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer112, 2500–2508 (2008).
   PubMed Web of Science ®Google Scholar
• Gressent SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann. Pharmacother.43, 490–501 (2009).
   PubMed Web of Science ®Google Scholar